InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Thursday, 08/04/2022 6:53:18 AM

Thursday, August 04, 2022 6:53:18 AM

Post# of 172
Mizuho Securities Initiates a Buy Rating on Bioxcel Therapeutics (BTAI)
August 04 2022 - 06:05AM

In a report released today, Graig Suvannavejh from Mizuho Securities initiated coverage with a Buy rating on Bioxcel Therapeutics (BTAI – Research Report) and a price target of $19.00. The company's shares closed last Wednesday at $14.91. According to TipRanks.com, Suvannavejh is a 2-star analyst with an average return of 0.7% and a 49.0% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Harmony Biosciences Holdings, and Intra-Cellular Therapies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BTAI News